Jan 29, 2016 by Brian Orelli, PhDWhy Exelixis, Inc. Rocketed Higher on FridayAn upcoming catalyst gets amplified by the gyrating biotech sentiment.
Jan 28, 2016 by Brian Orelli, PhDCelldex Therapeutics, Inc. Gets Rocked as Data ApproachesSome investors think the biotech is about to face some bad news.
Jan 28, 2016 by Brian Orelli, PhDCelgene Corporation Looks ForwardEarnings releases aren't particularly useful when the biotech has already released preliminary numbers.
Jan 27, 2016 by Brian Orelli, PhDNatus Medical Inc. Serving Up Earning GrowthGrowth in its services businesses is key for the medical-device maker.
Jan 27, 2016 by Brian Orelli, PhDThe Big Question for Celgene Corporation's ManagementWith preliminary earnings numbers released, here's what investors should focus on during the earnings call.
Jan 26, 2016 by Brian Orelli, PhD1 Thing to Watch As Natus Medical Inc. Reports EarningsWhat's the acquisition specialist's next move?
Jan 22, 2016 by Brian Orelli, PhDWhy Cardiovascular Systems Inc's Stock Flatlined TodayA revenue miss at the medical-device maker.
Jan 20, 2016 by Brian Orelli, PhDWhy The Medicines Company Acquired a Higher Price TodayUnnamed sources say the drug company is selling some or all of its assets.
Jan 19, 2016 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc.'s Most Important SlideFocus on the biotech's upcoming events.
Jan 15, 2016 by Brian Orelli, PhDIonis Pharmaceuticals Inc Takes It to the ExtremesShares are moving at the whim of market sentiment.
Jan 13, 2016 by Brian Orelli, PhDWhy BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc, and ImmunoGen, Inc. Got Clobbered TodayInvestors are shunning biotechs in 2016.
Jan 13, 2016 by Brian Orelli, PhDWhy Sagent Pharmaceuticals Inc. Jumped TodayConfirmed buyout rumors give investors confidence in an exit.
Jan 11, 2016 by Brian Orelli, PhDNo JP Morgan Conference Love for Ionis Pharmaceuticals Inc, Geron Corporation, and Medivation IncApparently, no news is bad news.
Jan 11, 2016 by Brian Orelli, PhDWhy Qiagen NV's Shares Guided Lower TodayPreliminary fourth-quarter earnings miss expectations.
Jan 8, 2016 by Brian Orelli, PhDWhy Momenta Pharmaceuticals, Inc. Was Up TodayA new partner to share costs with.
Jan 7, 2016 by Brian Orelli, PhDWhy Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked TodaySelling shares at a discount will do that.
Dec 24, 2015 by Brian Orelli, PhDCan MannKind Corporation's New CEO Save the Biotech?An all-time low for the biotech.
Dec 23, 2015 by Brian Orelli, PhDWhy Exelixis, Inc. Is Trading Higher TodayThe biotech submitted a marketing application for its kidney cancer drug.
Dec 22, 2015 by Brian Orelli, PhDThe Best Exelixis, Inc. Headlines in 2015The biotech reported a successful clinical trial and approval of another drug this year.
Dec 21, 2015 by Brian Orelli, PhDbluebird bio Inc: Gene Therapy Is (Still) HardLess than stellar data, but don't give up on the biotech just yet.
